Last reviewed · How we verify
Azacitidine and LDE255
At a glance
| Generic name | Azacitidine and LDE255 |
|---|---|
| Also known as | Vidaza |
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azacitidine and LDE255 CI brief — competitive landscape report
- Azacitidine and LDE255 updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI